Santen to acquire InnFocus
Santen Pharmaceutical announced on July 19, 2016, it has entered into a definitive agreement to acquire InnFocus, developer of the MicroShunt glaucoma implant device.
Santen will acquire InnFocus for an upfront payment of $225 million, plus performance-based considerations upon achievement of development, commercial and regulatory milestones, according to a press release.
The MicroShunt, which has a CE mark in Europe, is designed to lower and sustain IOP for the treatment of primary open-angle glaucoma. In clinical trials outside of the U.S., the device “has shown significant and sustainable lowering of IOP” alone or in combination with cataract surgery, according to the release.
“With this acquisition, Santen will strengthen our glaucoma pipeline and stay at the forefront of innovation in ophthalmology. This agreement is in line with our long-term vision to become a specialized pharmaceutical company with a global presence,” Akira Kurokawa, president and CEO of Santen, said in the release.
The MicroShunt is currently in late-stage clinical studies in the U.S. and Europe in advance of a premarket approval application to the FDA, according to the release.